CRSP logo

CRSP
CRISPR Therapeutics AG

41,719
Mkt Cap
$5.29B
Volume
1.73M
52W High
$78.48
52W Low
$34.87
PE Ratio
-8.83
CRSP Fundamentals
Price
$54.83
Prev Close
$52.42
Open
$53.05
50D MA
$52.21
Beta
1.54
Avg. Volume
1.73M
EPS (Annual)
-$6.47
P/B
2.91
$2,938.96
Loading...
Loading...
News
all
press releases
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Zacks·2d ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks·2d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 6.1% - What's Next?
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 6.1% - Here's Why...
MarketBeat·5d ago
News Placeholder
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
Zacks·5d ago
News Placeholder
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
Zacks·5d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.06 EPS
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.22) by...
MarketBeat·6d ago
News Placeholder
CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday
CRISPR Therapeutics (NASDAQ:CRSP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-crispr-therapeutics-ag-stock...
MarketBeat·6d ago
News Placeholder
Pictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSP
Pictet Asset Management Holding SA reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 167,464 shares of the company's stock after selling 25,129 shares during...
MarketBeat·7d ago
News Placeholder
UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP
UBS Group AG grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 7.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,524,144 shares of the company's stock after purchasing an a...
MarketBeat·9d ago
<
1
2
...
>

Latest CRSP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.